Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors

Overview

Journal Drugs

Specialty Pharmacology

Date 2019 Feb 24

PMID 30796733

Citations 15

Authors

Melinda Mata

Stephen Gottschalk

Affiliations

Soon will be listed here.

Abstract

While impressive clinical responses have been observed using chimeric antigen receptor (CAR) T cells targeting CD19+ hematologic malignancies, limited clinical benefit has been observed using CAR T cells for a variety of solid tumors. Results of clinical studies have highlighted several obstacles which CAR T cells face in the context of solid tumors, including insufficient homing to tumor sites, lack of expansion and persistence, encountering a highly immunosuppressive tumor microenvironment, and heterogeneous antigen expression. In this review, we review clinical outcomes and discuss strategies to improve the antitumor activity of CAR T cells for solid tumors.

Citing Articles

Car T Cells in Solid Tumors: Overcoming Obstacles.

Rojas-Quintero J, Diaz M, Palmar J, Galan-Freyle N, Morillo V, Escalona D Int J Mol Sci. 2024; 25(8).

PMID: 38673757 PMC: 11050550. DOI: 10.3390/ijms25084170.

Trogocytosis of CAR molecule regulates CAR-T cell dysfunction and tumor antigen escape.

Zhai Y, Du Y, Li G, Yu M, Hu H, Pan C Signal Transduct Target Ther. 2023; 8(1):457.

PMID: 38143263 PMC: 10749292. DOI: 10.1038/s41392-023-01708-w.

Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating.

Hamieh M, Mansilla-Soto J, Riviere I, Sadelain M Cancer Discov. 2023; 13(4):829-843.

PMID: 36961206 PMC: 10068450. DOI: 10.1158/2159-8290.CD-23-0101.

De novo-designed transmembrane domains tune engineered receptor functions.

Elazar A, Chandler N, Davey A, Weinstein J, Nguyen J, Trenker R Elife. 2022; 11.

PMID: 35506657 PMC: 9068223. DOI: 10.7554/eLife.75660.

Current status and hurdles for CAR-T cell immune therapy.

Zhao R, Cui Y, Li S, Qin L, Li P Blood Sci. 2022; 1(2):148-155.

PMID: 35402809 PMC: 8974909. DOI: 10.1097/BS9.0000000000000025.

References

Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J . Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010; 24(6):1160-70. PMC: 2888148. DOI: 10.1038/leu.2010.75. View

Foster A, Mahendravada A, Shinners N, Chang W, Crisostomo J, Lu A . Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40. Mol Ther. 2017; 25(9):2176-2188. PMC: 5589084. DOI: 10.1016/j.ymthe.2017.06.014. View

Young A, Mittal D, Stagg J, Smyth M . Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 2014; 4(8):879-88. DOI: 10.1158/2159-8290.CD-14-0341. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Krenciute G, Prinzing B, Yi Z, Wu M, Liu H, Dotti G . Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunol Res. 2017; 5(7):571-581. PMC: 5746871. DOI: 10.1158/2326-6066.CIR-16-0376. View

Long A, Haso W, Shern J, Wanhainen K, Murgai M, Ingaramo M . 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015; 21(6):581-90. PMC: 4458184. DOI: 10.1038/nm.3838. View

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

Rosenberg S . IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014; 192(12):5451-8. PMC: 6293462. DOI: 10.4049/jimmunol.1490019. View

Omer B, Castillo P, Tashiro H, Shum T, Huynh M, Cardenas M . Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. Front Med (Lausanne). 2019; 5:343. PMC: 6297364. DOI: 10.3389/fmed.2018.00343. View

10.

Abdelsamed H, Zebley C, Youngblood B . Epigenetic Maintenance of Acquired Gene Expression Programs during Memory CD8 T Cell Homeostasis. Front Immunol. 2018; 9:6. PMC: 5778141. DOI: 10.3389/fimmu.2018.00006. View

11.

Zhou X, Naik S, Dakhova O, Dotti G, Heslop H, Brenner M . Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Mol Ther. 2015; 24(4):823-31. PMC: 4886936. DOI: 10.1038/mt.2015.234. View

12.

Gattinoni L, Finkelstein S, Klebanoff C, Antony P, Palmer D, Spiess P . Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005; 202(7):907-12. PMC: 1397916. DOI: 10.1084/jem.20050732. View

13.

Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D . HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017; 3(8):1094-1101. PMC: 5747970. DOI: 10.1001/jamaoncol.2017.0184. View

14.

Vogler I, Newrzela S, Hartmann S, Schneider N, von Laer D, Koehl U . An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther. 2010; 18(7):1330-8. PMC: 2911262. DOI: 10.1038/mt.2010.83. View

15.

Ruella M, Barrett D, Kenderian S, Shestova O, Hofmann T, Perazzelli J . Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016; 126(10):3814-3826. PMC: 5096828. DOI: 10.1172/JCI87366. View

16.

Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y . Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA Metastatic Colorectal Cancers. Mol Ther. 2017; 25(5):1248-1258. PMC: 5417843. DOI: 10.1016/j.ymthe.2017.03.010. View

17.

Geiger R, Rieckmann J, Wolf T, Basso C, Feng Y, Fuhrer T . L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity. Cell. 2016; 167(3):829-842.e13. PMC: 5075284. DOI: 10.1016/j.cell.2016.09.031. View

18.

Kahlon K, Brown C, Cooper L, Raubitschek A, Forman S, Jensen M . Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004; 64(24):9160-6. DOI: 10.1158/0008-5472.CAN-04-0454. View

19.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

20.

Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L . HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997; 276(5319):1719-24. DOI: 10.1126/science.276.5319.1719. View